Literature DB >> 8726753

Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans.

K R Bonson1, J W Buckholtz, D L Murphy.   

Abstract

This study investigates the possible interactions of antidepressant agents and hallucinogens in humans through structured interviews using a standardized questionnaire. Volunteer subjects recruited through announcements placed on the Internet or other sources were asked to describe the somatic, hallucinatory, and psychological effects of self-administered LSD prior to and during chronic administration of an antidepressant. Twenty-eight out of 32 subjects (88%) who had taken an antidepressant with inhibitory effects on serotonin (5-HT) reuptake (fluoxetine, paroxetine, sertraline, trazodone) for over 3 weeks had a subjective decrease or virtual elimination of their responses to LSD. An additional subject who had taken fluoxetine for only 1 week had an increased response to LSD. These data are in contrast to our previous study that reported increased responses to LSD during chronic administration of tricyclic antidepressants or lithium. Possible mechanisms of action for the effects from serotonergic antidepressants involve 5-HT2 and 5-HT1A receptors, changes in extracellular brain serotonin concentrations, and changes in brain catecholamine systems.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8726753     DOI: 10.1016/0893-133X(95)00145-4

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  18 in total

1.  Characterization of the functional heterologous desensitization of hypothalamic 5-HT(1A) receptors after 5-HT(2A) receptor activation.

Authors:  Y Zhang; D D'Souza; D K Raap; F Garcia; G Battaglia; N A Muma; L D Van de Kar
Journal:  J Neurosci       Date:  2001-10-15       Impact factor: 6.167

Review 2.  Human hallucinogen research: guidelines for safety.

Authors:  Mw Johnson; Wa Richards; Rr Griffiths
Journal:  J Psychopharmacol       Date:  2008-07-01       Impact factor: 4.153

Review 3.  The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.

Authors:  Robin L Carhart-Harris; Guy M Goodwin
Journal:  Neuropsychopharmacology       Date:  2017-04-26       Impact factor: 7.853

4.  Interaction analysis between 5-HTTLPR and TNFA -238/-308 polymorphisms in schizophrenia.

Authors:  C-U Pae; A Serretti; P Artioli; T-S Kim; J-J Kim; C-U Lee; S-J Lee; I-H Paik; C Lee
Journal:  J Neural Transm (Vienna)       Date:  2005-10-27       Impact factor: 3.575

5.  New Onset LSD Flashback Syndrome Triggered by the Initiation of SSRIs.

Authors:  Sarah Goldman; David Galarneau; Richard Friedman
Journal:  Ochsner J       Date:  2007

6.  The 5-HT1A receptor and the stimulus effects of LSD in the rat.

Authors:  C J Reissig; J R Eckler; R A Rabin; J C Winter
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

Review 7.  Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research.

Authors:  David Bender; David J Hellerstein
Journal:  Psychopharmacology (Berl)       Date:  2022-01-13       Impact factor: 4.530

8.  Hallucinogen-persisting perception disorder.

Authors:  Leo Hermle; Melanie Simon; Martin Ruchsow; Martin Geppert
Journal:  Ther Adv Psychopharmacol       Date:  2012-10

Review 9.  Serotonin toxicity of serotonergic psychedelics.

Authors:  Benjamin Malcolm; Kelan Thomas
Journal:  Psychopharmacology (Berl)       Date:  2021-07-12       Impact factor: 4.530

10.  Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis.

Authors:  Patrick Vizeli; Isabelle Straumann; Friederike Holze; Yasmin Schmid; Patrick C Dolder; Matthias E Liechti
Journal:  Sci Rep       Date:  2021-05-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.